Literature DB >> 17315546

Opioid contract use is associated with physician training level and practice specialty.

Bryan Keith Touchet1, William Robert Yates, Kim Annette Coon.   

Abstract

Opioid contracts are widely used to manage opioid prescribing in the treatment of pain conditions, but they are not well studied. A notable gap in our knowledge of opioid contracts involves the factors that determine their use. As an initial inquiry, this study evaluated the responses of a Web-based survey of trainees and faculty in an academic medical training context to determine correlates of opioid contract use. All paid faculty, third- and fourth-year medical students, and residents in The University of Oklahoma College of Medicine were invited via email to participate in a Web-based survey of their attitudes and prescribing practices related to controlled prescription drugs. Respondents composing a subgroup of those who replied to the survey were identified by their prescription of opioids and by their designation that pain was the most likely diagnosis for which they would prescribe a controlled drug. Chi-square analysis was used to determine any correlation between contract use and respondents' demographic variables and categorical survey responses. Analysis of variance was used to determine any correlation between contract use and survey responses that involved continuous variables. Our results showed that opioid contract use was significantly associated with resident status, primary care specialty, participant estimation of alcohol and illicit drug abuse by patients, and the participant's assessment of the risks in general of prescribing controlled drugs. A majority of contract users reported that the use of this tool increased their sense of mastery and comfort with prescribing controlled drugs. The factors associated with opioid contract use found in this study suggest there are significant prescriber-specific determinants of the use of the tool, including training level, medical specialty, and risk appraisals. Opioid contracts' effects on mastery and comfort of the physician with prescribing opioids suggest that they may play an important role in facilitating appropriate pain management with opioids. Further study is needed to elucidate environmental and patient-specific factors that may influence opioid contract use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17315546     DOI: 10.5055/jom.2005.0042

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  5 in total

1.  Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain.

Authors:  Joanna L Starrels; William C Becker; Mark G Weiner; Xuan Li; Moonseong Heo; Barbara J Turner
Journal:  J Gen Intern Med       Date:  2011-02-24       Impact factor: 5.128

2.  Adherence to prescription opioid monitoring guidelines among residents and attending physicians in the primary care setting.

Authors:  Laila Khalid; Jane M Liebschutz; Ziming Xuan; Shernaz Dossabhoy; Yoona Kim; Denise Crooks; Christopher Shanahan; Allison Lange; Orlaith Heymann; Karen E Lasser
Journal:  Pain Med       Date:  2014-12-19       Impact factor: 3.750

3.  Primary care providers' views on chronic pain management among high-risk patients in safety net settings.

Authors:  Maya Vijayaraghavan; Joanne Penko; David Guzman; Christine Miaskowski; Margot B Kushel
Journal:  Pain Med       Date:  2012-07-30       Impact factor: 3.750

4.  Validation of a brief Opioid Compliance Checklist for patients with chronic pain.

Authors:  Robert N Jamison; Marc O Martel; Robert R Edwards; Jing Qian; Kerry Anne Sheehan; Edgar L Ross
Journal:  J Pain       Date:  2014-08-01       Impact factor: 5.820

5.  Healthcare system-wide implementation of opioid-safety guideline recommendations: the case of urine drug screening and opioid-patient suicide- and overdose-related events in the Veterans Health Administration.

Authors:  Penny L Brennan; Aaron C Del Re; Patricia T Henderson; Jodie A Trafton
Journal:  Transl Behav Med       Date:  2016-12       Impact factor: 3.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.